Karyopharm Therapeutics (STU:25K0) Institutional Ownership: 22.93% (As of Sep. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:25K0 Karyopharm Therapeutics Inc STU:25K0
50 GF Score
Price €1.54
GF Value €4.02
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Karyopharm Therapeutics Institutional Ownership?

Karyopharm Therapeutics STU:25K0 +2.67% 50 Institutional Ownership is 22.93% as of Sep. 05, 2026. GuruFocus rates STU:25K0 with a GF Score™ of 50/100 and a GF Value™ of €4.02 (Possible Value Trap). The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Karyopharm Therapeutics's institutional ownership is 22.93%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Karyopharm Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Karyopharm Therapeutics's Float Percentage Of Total Shares Outstanding is 99.50%.

Karyopharm Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Karyopharm Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Karyopharm Therapeutics Institutional Ownership Chart

Karyopharm Therapeutics Historical Data

The historical data trend for Karyopharm Therapeutics can be seen below:

2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31 2026-08-31
Institutional Ownership 12.97 14.89 16.68 16.82 15.08 13.55 13.45 21.44 23.44 22.93
STU:25K0
50GF Score
Karyopharm Therapeutics Inc STU:25K0
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Karyopharm Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 22.93% mean?
Karyopharm Therapeutics (STU:25K0) has a Institutional Ownership of 22.93% as of Sep. 05, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Karyopharm Therapeutics and its competitors.
Is Karyopharm Therapeutics' Institutional Ownership too high?
Karyopharm Therapeutics' current Institutional Ownership is 22.93%. Overall, Karyopharm Therapeutics has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Karyopharm Therapeutics' Institutional Ownership compare to ALGS and EDSA?
Karyopharm Therapeutics' Institutional Ownership of 22.93% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Karyopharm Therapeutics and its competitors. Karyopharm Therapeutics's current Institutional Ownership is 22.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Karyopharm Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Karyopharm Therapeutics (STU:25K0) is currently considered Possible Value Trap. The stock's GF Value™ is €4.02, compared to a current price of €1.54 — trading 61.7% below its estimated fair value. The current Institutional Ownership is 22.93%. Karyopharm Therapeutics' overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Karyopharm Therapeutics (STU:25K0), the current Institutional Ownership is 22.93% as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Karyopharm Therapeutics (STU:25K0) Overvalued in 2026?

Based on GuruFocus' analysis, Karyopharm Therapeutics stock appears to be undervalued. The current stock price of €1.54 is trading 61.7% below its estimated GF Value™ of €4.02. GuruFocus considers Karyopharm Therapeutics to be Possible Value Trap.

Key valuation signals for STU:25K0:

  • Institutional Ownership: 22.93%
  • GF Value™: €4.02 vs. price of €1.54 (61.7% below fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the STU:25K0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Karyopharm Therapeutics Business Description

Other Exchanges KPTI:USA
Address 85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
50GF Score

Get the complete analysis for STU:25K0

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.54
Price
€4.02
GF Value